Premature ovarian insufficiency: how to improve reproductive outcome?

被引:27
作者
Ben-Nagi, J. [1 ]
Panay, N. [1 ,2 ]
机构
[1] Chelsea & Westminster Hosp, West London Menopause & PMS Ctr, London SW10 9NH, England
[2] Queen Charlottes & Chelsea Hosp, West London Menopause & PMS Ctr, London W6 0XG, England
关键词
PREMATURE OVARIAN INSUFFICIENCY; HORMONE REPLACEMENT THERAPY; CONTRACEPTIVE PILL; PLACEBO-CONTROLLED TRIAL; HORMONE-REPLACEMENT THERAPY; OVULATION INDUCTION; GONADOTROPIN SUPPRESSION; DEHYDROEPIANDROSTERONE SUPPLEMENTATION; CLOMIPHENE CITRATE; FAILURE; PREGNANCY; WOMEN; STIMULATION;
D O I
10.3109/13697137.2013.860115
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Premature ovarian insufficiency (POI) is a life-changing condition that affects women in their reproductive age. The condition is not necessarily permanent but is associated with intermittent and unpredictable ovarian activity. Hence, spontaneous pregnancies have been reported to be 5-10%. However, pregnancy in patients with POI is still unlikely and rare. Although, there are reviews on POI in the literature, there is a lack of reports which focus on how to improve the reproductive outcome of these women who wish to conceive spontaneously or use assisted conception with their own oocytes. We found that there is no conclusive evidence of which treatment is optimal for women with POI who wish to conceive using their own gametes. However, one could surmise that it is important to lower gonadotropin levels into the physiological range before embarking on any treatment, even if natural conception is the only choice for the woman/couple. In the future, multi-center, randomized, double-blind, placebo-controlled trials should be carried out, which may entail recruitment of patients from various centers nationally and internationally to increase the sample size and therefore achieve a powered study. This may standardize the treatment of women with POI who wish to conceive and ultimately have their biological child.
引用
收藏
页码:242 / 246
页数:5
相关论文
共 37 条
[31]   GONADOTROPINS ENHANCE HLA-DR ANTIGEN EXPRESSION IN HUMAN GRANULOSA-CELLS [J].
TIDEY, GF ;
NELSON, LM ;
PHILLIPS, TM ;
STILLMAN, RJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (06) :1768-1773
[32]   Corticosteroids do not influence ovarian responsiveness to gonadotropins in patients with premature ovarian failure: a randomized, placebo-controlled trial [J].
van Kasteren, YM ;
Braat, DDM ;
Hemrika, DJ ;
Lambalk, CB ;
Rekers-Mombarg, LTM ;
von Blomberg, BME ;
Schoemaker, J .
FERTILITY AND STERILITY, 1999, 71 (01) :90-95
[33]   Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy [J].
van Kasteren, YM ;
Schoemaker, J .
HUMAN REPRODUCTION UPDATE, 1999, 5 (05) :483-492
[34]   Premature ovarian failure and pregnancy [J].
Vandborg M. ;
Lauszus F.F. .
Archives of Gynecology and Obstetrics, 2006, 273 (6) :387-388
[35]   OVULATION INDUCTION IN PREMATURE OVARIAN FAILURE - A PLACEBO-CONTROLLED RANDOMIZED TRIAL COMBINING PITUITARY SUPPRESSION WITH GONADOTROPIN STIMULATION [J].
VANKASTEREN, YM ;
HOEK, A ;
SCHOEMAKER, J .
FERTILITY AND STERILITY, 1995, 64 (02) :273-278
[36]   A Randomized Double-Blinded Placebo-Controlled Trial on the Effect of Dehydroepiandrosterone for 16 Weeks on Ovarian Response Markers in Women with Primary Ovarian Insufficiency [J].
Yeung, Tracy Wing Yee ;
Li, Raymond Hang Wun ;
Lee, Vivian Chi Yan ;
Ho, Pak Chung ;
Ng, Ernest Hung Yu .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01) :380-388
[37]  
Zargar A H, 2000, J Assoc Physicians India, V48, P213